---
title: 'Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical
  Benefit, Innovation, Epidemiology, and Competition'
date: '2023-10-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37855850/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231019180803&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Cancer drug prices regularly increase faster than inflation;
  however, there is no evidence that launch prices and post-launch price changes are
  aligned with the clinical benefit a drug offers to patients. In particular, patients
  with rare diseases experience greater price increases for their orphan drugs. There
  is no evidence that brand-brand competition results in drug price ...'
disable_comments: true
---
CONCLUSIONS: Cancer drug prices regularly increase faster than inflation; however, there is no evidence that launch prices and post-launch price changes are aligned with the clinical benefit a drug offers to patients. In particular, patients with rare diseases experience greater price increases for their orphan drugs. There is no evidence that brand-brand competition results in drug price ...